Literature DB >> 19811383

Hypertension, systemic inflammation and body weight in relation to lung function impairment-an epidemiological study.

Olof Birna Margretardottir1, Sigurdur James Thorleifsson, Gunnar Gudmundsson, Isleifur Olafsson, Bryndis Benediktsdottir, Christer Janson, A Sonia Buist, Thorarinn Gislason.   

Abstract

Recent reports on the simultaneous occurrence of systemic inflammation and airflow obstruction are usually based on a highly selective patient population, but their importance warrants further evaluation in the general population. The objectives were to study the interrelationship between airflow obstruction, smoking, hypertension, obesity and CRP as a marker of systemic inflammation in a randomly selected sample of the general Icelandic population (n = 939). This study comprised 758 randomly selected men and women 40 years and older living in Reykjavik, Iceland, and who were participating in the Burden of Obstructive Lung Disease (BOLD) study (81% response rate). In addition to the BOLD protocol, which included post-bronchodilator spirometry, they answered questions about general health and medication. Serum samples were taken for measurement of C-reactive protein (CRP). In the sample-245 individuals (33%) reported having hypertension. Subjects with hypertension were older, had a higher BMI and higher CRP levels. Subjects with hypertension had lower values of FEV(1) than predicted (89.9 +/- 18.5 vs. 94.5 +/- 14.4%) (p < 0.001) and FVC (92.2 +/- 15.1 vs. 95.3 +/- 12.3%) (p = 0.002). These differences remained significant after adjusting for age, BMI, CRP and smoking. Hypertension and CRP levels above the median were both independently and additively associated with lower FEV(1) and FVC. In addition a lower FVC% was also associated with a higher BMI (> 30 mg/m2). Use of betablocking antihypertensives was not related to lung function. Hypertension, BMI and systemic inflammation affect lung function independently of each other. All three variables have a negative effect on FVC, while hypertension and high CRP were independently associated with impaired FEV(1).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811383      PMCID: PMC3334274          DOI: 10.1080/15412550903049157

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  29 in total

1.  Markers of disease severity in chronic obstructive pulmonary disease.

Authors:  Luigi G Franciosi; Clive P Page; Bartolome R Celli; Mario Cazzola; Michael J Walker; Meindert Danhof; Klaus F Rabe; Oscar E Della Pasqua
Journal:  Pulm Pharmacol Ther       Date:  2005-07-12       Impact factor: 3.410

Review 2.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

3.  C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study.

Authors:  I S Olafsdottir; T Gislason; B Thjodleifsson; I Olafsson; D Gislason; R Jögi; C Janson
Journal:  Thorax       Date:  2005-06       Impact factor: 9.139

4.  Raised CRP levels mark metabolic and functional impairment in advanced COPD.

Authors:  R Broekhuizen; E F M Wouters; E C Creutzberg; A M W J Schols
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

5.  Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.

Authors:  Caroline S Fox; Joseph M Massaro; Udo Hoffmann; Karla M Pou; Pal Maurovich-Horvat; Chun-Yu Liu; Ramachandran S Vasan; Joanne M Murabito; James B Meigs; L Adrienne Cupples; Ralph B D'Agostino; Christopher J O'Donnell
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

6.  Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women.

Authors:  Jamal S Rana; Murray A Mittleman; Javed Sheikh; Frank B Hu; JoAnn E Manson; Graham A Colditz; Frank E Speizer; R Graham Barr; Carlos A Camargo
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

7.  Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation.

Authors:  Naomi Hosogai; Atsunori Fukuhara; Kazuya Oshima; Yugo Miyata; Sachiyo Tanaka; Katsumori Segawa; Shigetada Furukawa; Yoshihiro Tochino; Ryutaro Komuro; Morihiro Matsuda; Iichiro Shimomura
Journal:  Diabetes       Date:  2007-04       Impact factor: 9.461

8.  Obesity in adulthood and its consequences for life expectancy: a life-table analysis.

Authors:  Anna Peeters; Jan J Barendregt; Frans Willekens; Johan P Mackenbach; Abdullah Al Mamun; Luc Bonneux
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

9.  Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease.

Authors:  Yvette R B M van Gestel; Sanne E Hoeks; Don D Sin; Cihan Simsek; Gijs M J M Welten; Olaf Schouten; Henk Stam; Frans W Mertens; Ron T van Domburg; Don Poldermans
Journal:  Am J Cardiol       Date:  2008-05-28       Impact factor: 2.778

Review 10.  Osteoporosis in chronic obstructive pulmonary disease patients.

Authors:  Niklas Rye Jørgensen; Peter Schwarz
Journal:  Curr Opin Pulm Med       Date:  2008-03       Impact factor: 3.155

View more
  21 in total

1.  Long-Term Effects of Ambient PM2.5 on Hypertension and Blood Pressure and Attributable Risk Among Older Chinese Adults.

Authors:  Hualiang Lin; Yanfei Guo; Yang Zheng; Qian Di; Tao Liu; Jianpeng Xiao; Xing Li; Weilin Zeng; Lenise A Cummings-Vaughn; Steven W Howard; Michael G Vaughn; Zhengmin Min Qian; Wenjun Ma; Fan Wu
Journal:  Hypertension       Date:  2017-03-27       Impact factor: 10.190

2.  Linking physiological parameters to perturbations in the human exposome: Environmental exposures modify blood pressure and lung function via inflammatory cytokine pathway.

Authors:  Matthew A Stiegel; Joachim D Pleil; Jon R Sobus; Tina Stevens; Michael C Madden
Journal:  J Toxicol Environ Health A       Date:  2017-07-11

3.  Gender influences the relationship between lung function and cardiac remodeling in hypertensive subjects.

Authors:  Paulo R Mendes; Tatiana A Kiyota; José A Cipolli; Roberto Schreiber; Layde R Paim; Vera R Bellinazzi; José R Matos-Souza; Andrei C Sposito; Wilson Nadruz
Journal:  Hypertens Res       Date:  2014-11-27       Impact factor: 3.872

Review 4.  Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives.

Authors:  Ruzena Tkacova
Journal:  Mediators Inflamm       Date:  2010-04-20       Impact factor: 4.711

5.  Regional differences in prediction models of lung function in Germany.

Authors:  Eva Schnabel; Chih-Mei Chen; Beate Koch; Stefan Karrasch; Rudolf A Jörres; Torsten Schäfer; Claus Vogelmeier; Ralf Ewert; Christoph Schäper; Henry Völzke; Anne Obst; Stephan B Felix; H-Erich Wichmann; Sven Gläser; Joachim Heinrich
Journal:  Respir Res       Date:  2010-04-22

6.  Effect of post recruitment maneuver ventilation by different tidal volume on lung vascular endothelial diastole function in rats with acute lung injury.

Authors:  Jian-Qiang Wang; Chun Pan; Lin Liu; Liang Jin; Yi Yang; Hai-Bo Qiu
Journal:  World J Emerg Med       Date:  2011

7.  Pharmacological potentiation of the efferent vagus nerve attenuates blood pressure and renal injury in a murine model of systemic lupus erythematosus.

Authors:  Grace S Pham; Lei A Wang; Keisa W Mathis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-10-17       Impact factor: 3.619

8.  Relationship between daily exposure to biomass fuel smoke and blood pressure in high-altitude Peru.

Authors:  Melissa Burroughs Peña; Karina M Romero; Eric J Velazquez; Victor G Davila-Roman; Robert H Gilman; Robert A Wise; J Jaime Miranda; William Checkley
Journal:  Hypertension       Date:  2015-03-09       Impact factor: 10.190

Review 9.  β-blockade: benefits beyond blood pressure reduction?

Authors:  John R Cockcroft; Michala E Pedersen
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-11       Impact factor: 3.738

10.  Prevalence of obstructive airway disease by spirometric indices in non-smoker subjects with IHD and HTN.

Authors:  Virendra C Patil; Bhupal N Pujari; Harsha V Patil; Amit Munjal; Vaibhav Agrawal
Journal:  Lung India       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.